Largest multinational survey highlights impact of pruritus on quality of life for patients with primary sclerosing cholangitis Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) presented data at the
Six-year natural history comparison with maralixibat demonstrates event-free and transplant-free survival in patients with Alagille syndrome Maralixibat data highlighting predictors of event-free